<DOC>
	<DOCNO>NCT02002650</DOCNO>
	<brief_summary>Acute pancreatitis common fear complication ERCP , occur 1 % 30 % procedure . Since 2012 , multicenter RCT publish NEJM , indomethacin use high risk patient consider `` standard '' method prevent PEP . However , risk factor PEP fully clear . Rectal indomethacin ERCP patient , select high-risk patient , may prevent PEP maximum . The purpose study determine whether routine use rectal indomethacin effective conditional strategy .</brief_summary>
	<brief_title>Rectal Indomethacin Prevent Post-ERCP Pancreatitis</brief_title>
	<detailed_description />
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Indomethacin</mesh_term>
	<criteria>Patients undergo diagnostic therapeutic ERCP . Unwillingness inability consent study ; Age &lt; 18 year old ; Intrauterine pregnancy ; Breastfeeding mother ; Standard contraindication ERCP ; Allergy NSAIDs ; Received NSAIDs prior 7 day ; Renal failure ( Cr &gt; 1.4mg/dl=120umol/l ) ; Active recurrent ( within 4 week ) gastrointestinal hemorrhage ; Acute pancreatitis within 72 hour ; Known pancreatic head mass ; Subject prior biliary sphincterotomy schedule repeat biliary therapy without anticipated pancreatogram ; ERCP biliary stent removal exchange without anticipated pancreatogram ; Known active cardiovascular cerebrovascular disease . Presence coagulopathy procedure receive anticoagulation therapy within three day procedure ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Indomethacin , pancreatitis , ERCP</keyword>
</DOC>